106 CHAPTER 2.2 Table SI1.6. START - Clarity rating of actions, from lowest to highest ranking. START Action Clarity rating n=34 E3 Vitamin D and calcium supplement 17% H1 High-potency opioids 17% H2 Laxatives 17% A4 Antihypertensive therapy 25% C2 Non-TCA antidepressant drug 25% E1 Disease-modifying anti-rheumatic drug (DMARD) 25% E4 Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate, strontium ranelate, teriparatide, denosumab) 42% E5 Vitamin D supplement 42% C3 Acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) 50% D2 Fibre supplements (e.g. bran, ispaghula, methylcellulose, sterculia) 50% E6 Xanthine-oxidase inhibitors (e.g. allopurinol, febuxostat) 50% B1 Regular inhaled B2 agonist or antimuscarinic bronchodilator (e.g. ipratropium, tiotropium) 58% B2 Regular inhaled corticosteroid 58% A1 Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors 67% A5 Statin therapy 67% A6 Angiotensin Converting Enzyme (ACE) inhibitor 67% A7 Beta-blocker 67% C1 L-DOPA or a dopamine agonist 67% C4 Topical prostaglandin, prostamide or beta-blocker 67% C5 Selective serotonin reuptake inhibitor (or SNRI or pregabalin if SSRI contraindicated) 67% D1 Proton Pump Inhibitor 67% E2 Bisphosphonates and vitamin D and calcium 67% F1 ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor) 67% G1 Alpha-1 receptor blocker 67% G2 5-alpha reductase inhibitor 67% A3 Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) 75% A8 Appropriate beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) 83% B3 Home continuous oxygen 83% C6 Dopamine agonist (ropinirole or pramipexole or rotigotine) 83% G3 Topical vaginal oestrogen or vaginal oestrogen pessary 83% I1 Seasonal trivalent influenza vaccine 83% I2 Pneumococcal vaccine 83% A2 Aspirin (75 mg – 160 mg once daily) 92% E7 Folic acid supplement 92%
RkJQdWJsaXNoZXIy MTk4NDMw